Chinook Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - Seite 2

Presented additional information on Chinook’s emerging pipeline at ASN Kidney Week 2020 Reimagined, including:
°  a poster presentation on the phase 3 ALIGN trial design for atrasentan, a potent, selective endothelin A receptor (ET_A) antagonist,
°  a poster presentation on healthy volunteer data from Part 1 (single ascending dose) and Part 2 (multiple ascending dose) of the ongoing phase 1 study of BION-1301, a novel anti-APRIL monoclonal antibody, and
°  an oral presentation on a single cell transcriptomic atlas of human autosomal dominant polycystic kidney disease (ADPKD) through Chinook’s academic collaboration with the laboratory of Benjamin Humphreys, M.D., Ph.D., Joseph Friedman Professor of Renal Diseases in Medicine and Chief of Nephrology at Washington University School of Medicine in St. Louis.

Anticipated Upcoming Catalysts

• Chinook plans to begin enrollment of its phase 3 ALIGN trial (see www.clinicaltrials.gov, identifier NCT04573478) in early 2021 to assess the efficacy, safety and tolerability of atrasentan in IgAN patients at risk of progressive kidney function loss. Atrasentan has previously been evaluated in over 5,300 diabetic kidney disease (DKD) patients in studies that demonstrated clinically significant and sustained reductions in proteinuria, as well as reduced risk of kidney function decline, when administered on top of a maximally tolerated dose of a RAS inhibitor (RASi).
  
  
• Chinook plans to begin enrollment of its phase 2 AFFINITY basket trial of atrasentan in the first half of 2021 to evaluate its therapeutic potential in multiple types of chronic kidney disease. Cohorts in the basket study include patients with: IgAN with proteinuria between 0.5 grams to less than one gram per day, focal segmental glomerular sclerosis (FSGS), Alport Syndrome and DKD in combination with SGLT2 inhibitors.
  
  
• Part 3 of Chinook’s phase 1 study of BION-1301 is currently enrolling adult patients with IgAN in an open-label setting and Chinook expects to present data in 2021. A phase 1 IV to subcutaneous (SC) bioavailability study in healthy volunteers is ongoing with the potential to transition to SC administration of BION-1301 in the long-term extension and phase 2 studies.
  
  
• Chinook plans to begin enrollment of its phase 1 study of CHK-336 in the second half of 2021.

Unaudited financial statements for Aduro Biotech, Inc. (Aduro) for the quarter and nine months ended September 30, 2020 can be found in our quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC). As the merger between Aduro and Chinook did not close until October 5, 2020, the historical financial statements presented on Form 10-Q reflect the financial position, results of operations and cash flows of Aduro.